半乳糖凝集素-3在相关疾病中的研究进展
|
摘要
半乳糖凝集素-3是半乳糖凝集素家族中的重要一员,其在许多病理生理过程中发挥作用,例如炎症反应、纤维化、细胞增殖及凋亡、血管生成、免疫反应等。越来越多的证据表明半乳糖凝集素-3参与了多种疾病的发生发展,本文就其在相关疾病中的研究进展作一综述,以期为临床治疗提供依据。
As an important member in galectin family,galectin-3 plays a role in many pathophysiological processes,such as:Inflammatory response,fibrosis,cell proliferation and apoptosis,angiogenesis,immune response.There is increasing evidence that galectin-3 is involved in the development of a variety of diseases. This article reviews the research progress of galectin-3 in related diseases,in order to provide basis for clinical treatment.
As an important member in galectin family,galectin-3 plays a role in many pathophysiological processes,such as:Inflammatory response,fibrosis,cell proliferation and apoptosis,angiogenesis,immune response.There is increasing evidence that galectin-3 is involved in the development of a variety of diseases. This article reviews the research progress of galectin-3 in related diseases,in order to provide basis for clinical treatment.
引文
[1]DESMEDT V,DESMEDT S,DELANGHE J R,et al.Galectin-3 in renal pathology:More than just an innocent bystander[J].Am J Nephrol,2016,43(5):305-317.
[2]HU Y,YéLéHé-OKOUMA M,EA H K,et al.Galectin-3:Akey player in arthritis[J].Joint Bone Spine,2016,84(1):15-20.
[3]DUMIC J,DABELIC S,FL?GEL M.Galectin-3:An openended story[J].Biochim Biophys Acta,2006,1760(4):616-635.
[4]SUTHAHAR N,MEIJERS W C,SILLJE H H W,et al.Galectin-3 activation and inhibition in heart failure and cardiovascular disease:An update[J].Theranostics,2018,8(3):593-609.
[5]LEE Y J,KOH Y S,PARK H E,et al.Spatial and temporal expression,and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis[J].Korean Circ J,2013,43(4):223-230.
[6]OYENUGA A,FOLSOM A R,FASHANU O,et al.Plasma galectin-3 and sonographic measures of carotid atherosclerosis in the atherosclerosis risk in communities study[J].Angiology,2018 Jan 1:3319718780772.
[7]MACKINNON A C,LIU X,HADOKE P W,et al.Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice[J].Glycobiology,2013,23(6):654-663.
[8]LU Y,ZHANG M,ZHAO P,et al.Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice[J].Mol Med Rep,2017,16(1):647-653.
[9]AKSAN G,GEDIKLI?,KESKIN K,et al.Is galectin-3 a biomarker,a player-or both-in the presence of coronary atherosclerosis?[J].J Investig Med,2016,64(3):764-770.
[10]KANG Q,LI X,YANG M,et al.Galectin-3 in patients with coronary heart disease and atrial fibrillation[J].Clin Chim Acta,2017,478:166-170.
[11]TIAN L,CHEN K,CAO J,et al.Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells[J].Mol Med Rep,2015,12(4):4995-5002.
[12]颜文华,李新华,赵晓燕,等.冠心病患者血清半乳糖凝集素3水平与冠状动脉斑块成分的相关性分析[J].中国动脉硬化杂志,2015,23(12):1268-1272.
[13]MAIOLINO G,ROSSITTO G,PEDON L,et al.Galectin-3predicts long-term cardiovascular death in high-risk patients with coronary artery disease[J].Arterioscler Thromb Vasc Biol,2015,35(3):725-732.
[14]SHARMA U C,MOSLEH W,CHAUDHARI M R,et al.Myocardial and serum galectin-3 expression dynamics marks post-myocardial infarction cardiac remodelling[J].Heart Lung Circ,2017,26(7):736-745.
[15]MOSLEH W,CHAUDHARI M R,SONKAWADE S,et al.The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region:A clinical outcome-based translational study[J].Biomark Insights,2018,13:1177271918771969.
[16]FILIPE M D,MEIJERS W C,ROGIER van der VELDE A,et al.Galectin-3 and heart failure:Prognosis,prediction&clinical utility[J].Clin Chim Acta,2015,443:48-56.
[17]ROGIER van der VELDE A,MEIJERS W C,HO J E,et al.Serial galectin-3 and future cardiovascular disease in the general population-Data of PREVEND[J].JACC,2016,67(13):1320.
[18]IMRAN T F,SHIN H J,MATHENGE N,et al.Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population[J].Am J Cardiol,2017,119(1):57-64.
[19]MIRóò,GONZáLEZ de la PRESA B,HERRERO-PUENTEP,et al.The GALA study:Relationship between galectin-3serum levels and short-and long-term outcomes of patients with acute heart failure[J].Biomarkers,2017,22(8):731-739.
[20]van VARK L C,LESMAN-LEEGTE I,BAART S J,et al.Prognostic value of serial galectin-3 measurements in patients with acute heart failure[J].J Am Heart Assoc,2017,6(12).pii:e003700.
[21]AMIN H Z,AMIN L Z,WIJAYA I P.Galectin-3:A novel biomarker for the prognosis of heart failure[J].Clujul Med,2017,90(2):129-132.
[22]YU X,SUN Y,ZHAO Y,et al.Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure[J].Int Heart J,2015,56(3):314-318.
[23]van der VELDE A R,GULLESTAD L,UELAND T,et al.Prognostic value of changes in galectin-3 levels over time in patients with heart failure:Data from CORONA and COACH[J].Circ Heart Fail,2013,6(2):219-226.
[24]CHEN A,HOU W,ZHANG Y,et al.Prognostic value of serum galectin-3 in patients with heart failure:A meta-analysis[J].Int J Cardiol,2015,182:168-170.
[25]CLEMENTY N,PIVER E,BISSON A,et al.Galectin-3 in atrial fibrillation:Mechanisms and therapeutic implications[J].Int J Mol Sci,2018,19(4).pii:E976.
[26]HO J E,YIN X,LEVY D,et al.Galectin 3 and incident atrial fibrillation in the community[J].Am Heart J,2014,167(5):729-734.
[27]FASHANU O E,NORBY F L,AGUILAR D,et al.Galectin-3and incidence of atrial fibrillation:The atherosclerosis risk in communities(ARIC)study[J].Am Heart J,2017,192:19-25.
[28]CHEN D,PROCTER N,GOH V,et al.New onset atrial fibrillation is associated with elevated galectin-3 levels[J].Int JCardiol,2016,223:48-49.
[29]CLEMENTY N,BENHENDA N,PIVER E,et al.Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation[J].Sci Rep,2016,6:34357.
[30]AGOSTON-COLDEA L,LUPU S,PETROVAI D,et al.Correlations between echocardiographic parameters of right ventricular dysfunction and galectin-3 in patients with chronic obstructive pulmonary disease and pulmonary hypertension[J].Med Ultrason,2015,17(4):487-495.
[31]PILETTE C,COLINET B,KISS R,et al.Increased galectin-3expression and intra-epithelial neutrophils in small airways in severe COPD[J].Eur Respir J,2007,29(5):914-922.
[32]FENG W,WU X,LI S,et al.Association of serum galectin-3with the acute exacerbation of chronic obstructive pulmonary disease[J].Med Sci Monit,2017,23:4612-4618.
[33]MAZUREK J A,HORNE B D,SAEED W,et al.Galectin-3levels are elevated and predictive of mortality in pulmonary hypertension[J].Heart Lung Circ,2017,26(11):1208-1215.
[34]FENSTER B E,LASALVIA L,SCHROEDER J D,et al.Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension[J].Heart Vessels,2016,31(6):939-946.
[35]GUO S,FENG Z.Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension[J].Int J Clin Exp Med,2015,8(9):15302-15307.
[36]BARMAN S A,CHEN F,LI X,et al.Galectin-3 promotes vascular remodeling and contributes to pulmonary hypertension[J].Am J Respir Crit Care Med,2018,197(11):1488-1492.
[37]ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney diseasein China:A cross-sectional surrey[J].Lancet,2012,379(9818):815-822.
[38]HENDERSON N C,MACKINNON A C,FARNWORTH S L,et al.Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis[J].Am J Pathol,2008,172(2):288-298.
[39]REBHOLZ C M,SELVIN E,LIANG M,et al.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease[J].Kidney Int,2018,93(1):252-259.
[40]SONG L,TANG J W,OWUSU L,et al.Galectin-3 in cancer[J].Clin Chim Acta,2014,431:185-191.
[41]ARCOLIA V,JOURNE F,RENAUD F,et al.Combination of galectin-3,CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer[J].Oncol Lett,2017,14(4):4183-4189.
[42]LIU X H,DENG C X,HU P C,et al.Functional impact of Galectin-3 and TRAIL expression in breast cancer cells[J].Eur Rev Med Pharmacol Sci,2017,21(16):3626-3633.
[43]AJANI J A,ESTRELLA J S,CHEN Q,et al.Galectin-3expression is prognostic in diffuse type gastric adenocarcinoma,confers aggressive phenotype,and can be targeted by YAP1/BET inhibitors[J].Br J Cancer,2018,118(1):52-61.
[44]STIASNY A,FREIER C P,KUHN C,et al.The involvement of E6,p53,p16,MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer[J].Oncol Lett,2017,14(4):4467-4476.
[45]KUO H Y,HSU H T,CHEN Y C,et al.Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer[J].Glycobiology,2016,26(2):155-165.
[46]ZHOU W,CHEN X,HU Q,et al.Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression[J].BMC Cancer,2018,18(1):580.
[47]刘美燕,杜冰,李春红,等.半乳凝素-3在非小细胞肺癌中的表达及相关性研究[J].中国肺癌杂志,2013,16(8):417-421.
[48]AHMED H,ALSADEK D M.Galectin-3 as a potential target to prevent cancer metastasis[J].Clin Med Insights Oncol,2015,9:113-121.
[49]UCHINO Y,MAURIS J,WOODWARD A M,et al.Alteration of galectin-3 in tears of patients with dry eye disease[J].Am JOphthalmol,2015,159(6):1027-1035.
[50]YAN Y P,LANG B T,VEMUGANTI R,et al.Galectin-3mediates post-ischemic tissue remodeling[J].Brain Res,2009,1288:116-124.
[51]WANG A,ZHONG C,ZHU Z,et al.Serum galectin-3 and poor outcomes among patients with acute ischemic stroke[J].Stroke,2018,49(1):211-214.
[2]HU Y,YéLéHé-OKOUMA M,EA H K,et al.Galectin-3:Akey player in arthritis[J].Joint Bone Spine,2016,84(1):15-20.
[3]DUMIC J,DABELIC S,FL?GEL M.Galectin-3:An openended story[J].Biochim Biophys Acta,2006,1760(4):616-635.
[4]SUTHAHAR N,MEIJERS W C,SILLJE H H W,et al.Galectin-3 activation and inhibition in heart failure and cardiovascular disease:An update[J].Theranostics,2018,8(3):593-609.
[5]LEE Y J,KOH Y S,PARK H E,et al.Spatial and temporal expression,and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis[J].Korean Circ J,2013,43(4):223-230.
[6]OYENUGA A,FOLSOM A R,FASHANU O,et al.Plasma galectin-3 and sonographic measures of carotid atherosclerosis in the atherosclerosis risk in communities study[J].Angiology,2018 Jan 1:3319718780772.
[7]MACKINNON A C,LIU X,HADOKE P W,et al.Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice[J].Glycobiology,2013,23(6):654-663.
[8]LU Y,ZHANG M,ZHAO P,et al.Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice[J].Mol Med Rep,2017,16(1):647-653.
[9]AKSAN G,GEDIKLI?,KESKIN K,et al.Is galectin-3 a biomarker,a player-or both-in the presence of coronary atherosclerosis?[J].J Investig Med,2016,64(3):764-770.
[10]KANG Q,LI X,YANG M,et al.Galectin-3 in patients with coronary heart disease and atrial fibrillation[J].Clin Chim Acta,2017,478:166-170.
[11]TIAN L,CHEN K,CAO J,et al.Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells[J].Mol Med Rep,2015,12(4):4995-5002.
[12]颜文华,李新华,赵晓燕,等.冠心病患者血清半乳糖凝集素3水平与冠状动脉斑块成分的相关性分析[J].中国动脉硬化杂志,2015,23(12):1268-1272.
[13]MAIOLINO G,ROSSITTO G,PEDON L,et al.Galectin-3predicts long-term cardiovascular death in high-risk patients with coronary artery disease[J].Arterioscler Thromb Vasc Biol,2015,35(3):725-732.
[14]SHARMA U C,MOSLEH W,CHAUDHARI M R,et al.Myocardial and serum galectin-3 expression dynamics marks post-myocardial infarction cardiac remodelling[J].Heart Lung Circ,2017,26(7):736-745.
[15]MOSLEH W,CHAUDHARI M R,SONKAWADE S,et al.The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region:A clinical outcome-based translational study[J].Biomark Insights,2018,13:1177271918771969.
[16]FILIPE M D,MEIJERS W C,ROGIER van der VELDE A,et al.Galectin-3 and heart failure:Prognosis,prediction&clinical utility[J].Clin Chim Acta,2015,443:48-56.
[17]ROGIER van der VELDE A,MEIJERS W C,HO J E,et al.Serial galectin-3 and future cardiovascular disease in the general population-Data of PREVEND[J].JACC,2016,67(13):1320.
[18]IMRAN T F,SHIN H J,MATHENGE N,et al.Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population[J].Am J Cardiol,2017,119(1):57-64.
[19]MIRóò,GONZáLEZ de la PRESA B,HERRERO-PUENTEP,et al.The GALA study:Relationship between galectin-3serum levels and short-and long-term outcomes of patients with acute heart failure[J].Biomarkers,2017,22(8):731-739.
[20]van VARK L C,LESMAN-LEEGTE I,BAART S J,et al.Prognostic value of serial galectin-3 measurements in patients with acute heart failure[J].J Am Heart Assoc,2017,6(12).pii:e003700.
[21]AMIN H Z,AMIN L Z,WIJAYA I P.Galectin-3:A novel biomarker for the prognosis of heart failure[J].Clujul Med,2017,90(2):129-132.
[22]YU X,SUN Y,ZHAO Y,et al.Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure[J].Int Heart J,2015,56(3):314-318.
[23]van der VELDE A R,GULLESTAD L,UELAND T,et al.Prognostic value of changes in galectin-3 levels over time in patients with heart failure:Data from CORONA and COACH[J].Circ Heart Fail,2013,6(2):219-226.
[24]CHEN A,HOU W,ZHANG Y,et al.Prognostic value of serum galectin-3 in patients with heart failure:A meta-analysis[J].Int J Cardiol,2015,182:168-170.
[25]CLEMENTY N,PIVER E,BISSON A,et al.Galectin-3 in atrial fibrillation:Mechanisms and therapeutic implications[J].Int J Mol Sci,2018,19(4).pii:E976.
[26]HO J E,YIN X,LEVY D,et al.Galectin 3 and incident atrial fibrillation in the community[J].Am Heart J,2014,167(5):729-734.
[27]FASHANU O E,NORBY F L,AGUILAR D,et al.Galectin-3and incidence of atrial fibrillation:The atherosclerosis risk in communities(ARIC)study[J].Am Heart J,2017,192:19-25.
[28]CHEN D,PROCTER N,GOH V,et al.New onset atrial fibrillation is associated with elevated galectin-3 levels[J].Int JCardiol,2016,223:48-49.
[29]CLEMENTY N,BENHENDA N,PIVER E,et al.Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation[J].Sci Rep,2016,6:34357.
[30]AGOSTON-COLDEA L,LUPU S,PETROVAI D,et al.Correlations between echocardiographic parameters of right ventricular dysfunction and galectin-3 in patients with chronic obstructive pulmonary disease and pulmonary hypertension[J].Med Ultrason,2015,17(4):487-495.
[31]PILETTE C,COLINET B,KISS R,et al.Increased galectin-3expression and intra-epithelial neutrophils in small airways in severe COPD[J].Eur Respir J,2007,29(5):914-922.
[32]FENG W,WU X,LI S,et al.Association of serum galectin-3with the acute exacerbation of chronic obstructive pulmonary disease[J].Med Sci Monit,2017,23:4612-4618.
[33]MAZUREK J A,HORNE B D,SAEED W,et al.Galectin-3levels are elevated and predictive of mortality in pulmonary hypertension[J].Heart Lung Circ,2017,26(11):1208-1215.
[34]FENSTER B E,LASALVIA L,SCHROEDER J D,et al.Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension[J].Heart Vessels,2016,31(6):939-946.
[35]GUO S,FENG Z.Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension[J].Int J Clin Exp Med,2015,8(9):15302-15307.
[36]BARMAN S A,CHEN F,LI X,et al.Galectin-3 promotes vascular remodeling and contributes to pulmonary hypertension[J].Am J Respir Crit Care Med,2018,197(11):1488-1492.
[37]ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney diseasein China:A cross-sectional surrey[J].Lancet,2012,379(9818):815-822.
[38]HENDERSON N C,MACKINNON A C,FARNWORTH S L,et al.Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis[J].Am J Pathol,2008,172(2):288-298.
[39]REBHOLZ C M,SELVIN E,LIANG M,et al.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease[J].Kidney Int,2018,93(1):252-259.
[40]SONG L,TANG J W,OWUSU L,et al.Galectin-3 in cancer[J].Clin Chim Acta,2014,431:185-191.
[41]ARCOLIA V,JOURNE F,RENAUD F,et al.Combination of galectin-3,CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer[J].Oncol Lett,2017,14(4):4183-4189.
[42]LIU X H,DENG C X,HU P C,et al.Functional impact of Galectin-3 and TRAIL expression in breast cancer cells[J].Eur Rev Med Pharmacol Sci,2017,21(16):3626-3633.
[43]AJANI J A,ESTRELLA J S,CHEN Q,et al.Galectin-3expression is prognostic in diffuse type gastric adenocarcinoma,confers aggressive phenotype,and can be targeted by YAP1/BET inhibitors[J].Br J Cancer,2018,118(1):52-61.
[44]STIASNY A,FREIER C P,KUHN C,et al.The involvement of E6,p53,p16,MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer[J].Oncol Lett,2017,14(4):4467-4476.
[45]KUO H Y,HSU H T,CHEN Y C,et al.Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer[J].Glycobiology,2016,26(2):155-165.
[46]ZHOU W,CHEN X,HU Q,et al.Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression[J].BMC Cancer,2018,18(1):580.
[47]刘美燕,杜冰,李春红,等.半乳凝素-3在非小细胞肺癌中的表达及相关性研究[J].中国肺癌杂志,2013,16(8):417-421.
[48]AHMED H,ALSADEK D M.Galectin-3 as a potential target to prevent cancer metastasis[J].Clin Med Insights Oncol,2015,9:113-121.
[49]UCHINO Y,MAURIS J,WOODWARD A M,et al.Alteration of galectin-3 in tears of patients with dry eye disease[J].Am JOphthalmol,2015,159(6):1027-1035.
[50]YAN Y P,LANG B T,VEMUGANTI R,et al.Galectin-3mediates post-ischemic tissue remodeling[J].Brain Res,2009,1288:116-124.
[51]WANG A,ZHONG C,ZHU Z,et al.Serum galectin-3 and poor outcomes among patients with acute ischemic stroke[J].Stroke,2018,49(1):211-214.